Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Nociceptive Pathway in the Cockroach Periplaneta americana.

Emanuel S, Libersat F.

Front Physiol. 2019 Aug 21;10:1100. doi: 10.3389/fphys.2019.01100. eCollection 2019.

2.

Mind Control: How Parasites Manipulate Cognitive Functions in Their Insect Hosts.

Libersat F, Kaiser M, Emanuel S.

Front Psychol. 2018 May 1;9:572. doi: 10.3389/fpsyg.2018.00572. eCollection 2018.

3.

Do Quiescence and Wasp Venom-Induced Lethargy Share Common Neuronal Mechanisms in Cockroaches?

Emanuel S, Libersat F.

PLoS One. 2017 Jan 3;12(1):e0168032. doi: 10.1371/journal.pone.0168032. eCollection 2017.

4.

The discovery of macrocyclic XIAP antagonists from a DNA-programmed chemistry library, and their optimization to give lead compounds with in vivo antitumor activity.

Seigal BA, Connors WH, Fraley A, Borzilleri RM, Carter PH, Emanuel SL, Fargnoli J, Kim K, Lei M, Naglich JG, Pokross ME, Posy SL, Shen H, Surti N, Talbott R, Zhang Y, Terrett NK.

J Med Chem. 2015 Mar 26;58(6):2855-61. doi: 10.1021/jm501892g. Epub 2015 Mar 12.

5.

Discovery of potent heterodimeric antagonists of inhibitor of apoptosis proteins (IAPs) with sustained antitumor activity.

Perez HL, Chaudhry C, Emanuel SL, Fanslau C, Fargnoli J, Gan J, Kim KS, Lei M, Naglich JG, Traeger SC, Vuppugalla R, Wei DD, Vite GD, Talbott RL, Borzilleri RM.

J Med Chem. 2015 Feb 12;58(3):1556-62. doi: 10.1021/jm501482t. Epub 2015 Jan 23.

PMID:
25584393
6.

Discovery of tetrahydroisoquinoline-based bivalent heterodimeric IAP antagonists.

Kim KS, Zhang L, Williams D, Perez HL, Stang E, Borzilleri RM, Posy S, Lei M, Chaudhry C, Emanuel S, Talbott R.

Bioorg Med Chem Lett. 2014 Nov 1;24(21):5022-9. doi: 10.1016/j.bmcl.2014.09.022. Epub 2014 Sep 16.

PMID:
25278234
7.

Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial.

Koegelenberg CF, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, O'Brien JA, Smith C, Abdool-Gaffar MS, Emanuel S, Esterhuizen TM, Irusen EM.

JAMA. 2014 Jul;312(2):155-61. doi: 10.1001/jama.2014.7195.

PMID:
25005652
8.

The Dabigatran debate.

Kaba RA, Ara F, Ward DE, Emanuel S.

Glob Cardiol Sci Pract. 2014 Oct 16;2014(3):254-6. doi: 10.5339/gcsp.2014.41. eCollection 2014. No abstract available.

9.

[Clinical dilemma: an unusual case of ascites].

Romi H, Hausman M, Kachko L, Emanuel S.

Harefuah. 2012 Dec;151(12):662-4, 722. Hebrew.

PMID:
23330254
10.

Development of a carbon-14 labeling approach to support disposition studies with a pegylated biologic.

Wang H, Wang L, Cao K, Emanuel SL, Morin P, Lin Z, Shen G, Hosbach J, Zhang D, Bonacorsi S, Rodrigues AD, Yang Z.

Drug Metab Dispos. 2012 Sep;40(9):1677-85. doi: 10.1124/dmd.112.044792. Epub 2012 May 24.

PMID:
22627466
11.

Structures of adnectin/protein complexes reveal an expanded binding footprint.

Ramamurthy V, Krystek SR Jr, Bush A, Wei A, Emanuel SL, Das Gupta R, Janjua A, Cheng L, Murdock M, Abramczyk B, Cohen D, Lin Z, Morin P, Davis JH, Dabritz M, McLaughlin DC, Russo KA, Chao G, Wright MC, Jenny VA, Engle LJ, Furfine E, Sheriff S.

Structure. 2012 Feb 8;20(2):259-69. doi: 10.1016/j.str.2011.11.016.

12.

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.

Purandare AV, McDevitt TM, Wan H, You D, Penhallow B, Han X, Vuppugalla R, Zhang Y, Ruepp SU, Trainor GL, Lombardo L, Pedicord D, Gottardis MM, Ross-Macdonald P, de Silva H, Hosbach J, Emanuel SL, Blat Y, Fitzpatrick E, Taylor TL, McIntyre KW, Michaud E, Mulligan C, Lee FY, Woolfson A, Lasho TL, Pardanani A, Tefferi A, Lorenzi MV.

Leukemia. 2012 Feb;26(2):280-8. doi: 10.1038/leu.2011.292. Epub 2011 Oct 21.

PMID:
22015772
13.

Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.

Wong TW, Lee FY, Emanuel S, Fairchild C, Fargnoli J, Fink B, Gavai A, Hammell A, Henley B, Hilt C, Hunt JT, Krishnan B, Kukral D, Lewin A, Malone H, Norris D, Oppenheimer S, Vite G, Yu C.

Clin Cancer Res. 2011 Jun 15;17(12):4031-41. doi: 10.1158/1078-0432.CCR-10-3417. Epub 2011 Apr 29.

14.

A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor.

Emanuel SL, Engle LJ, Chao G, Zhu RR, Cao C, Lin Z, Yamniuk AP, Hosbach J, Brown J, Fitzpatrick E, Gokemeijer J, Morin P, Morse BA, Carvajal IM, Fabrizio D, Wright MC, Das Gupta R, Gosselin M, Cataldo D, Ryseck RP, Doyle ML, Wong TW, Camphausen RT, Cload ST, Marsh HN, Gottardis MM, Furfine ES.

MAbs. 2011 Jan-Feb;3(1):38-48. Epub 2011 Jan 1.

15.

Discovery of anticancer agents of diverse natural origin.

Kinghorn AD, Carcache de Blanco EJ, Chai HB, Orjala J, Farnsworth NR, Soejarto DD, Oberlies NH, Wani MC, Kroll DJ, Pearce CJ, Swanson SM, Kramer RA, Rose WC, Fairchild CR, Vite GD, Emanuel S, Jarjoura D, Cope FO.

Pure Appl Chem. 2009 Jan 1;81(6):1051-1063.

16.

Patients' motivations for participating in cardiovascular clinical trials: a local perspective.

Burgess LJ, Sulzer NU, Hoosain F, Leverton N, Bliganut S, Emanuel S.

Cardiovasc J Afr. 2009 Jul-Aug;20(4):220-3.

17.

7-[1H-Indol-2-yl]-2,3-dihydro-isoindol-1-ones as dual Aurora-A/VEGF-R2 kinase inhibitors: design, synthesis, and biological activity.

Hughes TV, Emanuel SL, O'Grady HR, Connolly PJ, Rugg C, Fuentes-Pesquera AR, Karnachi P, Alexander R, Middleton SA.

Bioorg Med Chem Lett. 2008 Sep 15;18(18):5130-3. doi: 10.1016/j.bmcl.2008.07.090. Epub 2008 Jul 26.

PMID:
18718756
18.

A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: design, synthesis, and biological activity.

Hughes TV, Xu G, Wetter SK, Connolly PJ, Emanuel SL, Karnachi P, Pollack SR, Pandey N, Adams M, Moreno-Mazza S, Middleton SA, Greenberger LM.

Bioorg Med Chem Lett. 2008 Sep 1;18(17):4896-9. doi: 10.1016/j.bmcl.2008.07.057. Epub 2008 Jul 17.

PMID:
18678484
19.

4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors.

Xu G, Abad MC, Connolly PJ, Neeper MP, Struble GT, Springer BA, Emanuel SL, Pandey N, Gruninger RH, Adams M, Moreno-Mazza S, Fuentes-Pesquera AR, Middleton SA.

Bioorg Med Chem Lett. 2008 Aug 15;18(16):4615-9. doi: 10.1016/j.bmcl.2008.07.020. Epub 2008 Jul 10.

PMID:
18653333
20.

Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.

Xu G, Searle LL, Hughes TV, Beck AK, Connolly PJ, Abad MC, Neeper MP, Struble GT, Springer BA, Emanuel SL, Gruninger RH, Pandey N, Adams M, Moreno-Mazza S, Fuentes-Pesquera AR, Middleton SA, Greenberger LM.

Bioorg Med Chem Lett. 2008 Jun 15;18(12):3495-9. doi: 10.1016/j.bmcl.2008.05.024. Epub 2008 May 10.

PMID:
18508264
21.

Clinical trial remuneration: the patients' perspective.

Burgess L, Sulzer N, Emanuel S.

S Afr Med J. 2008 Feb;98(2):95-7. No abstract available.

PMID:
18350200
22.

Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.

Emanuel SL, Hughes TV, Adams M, Rugg CA, Fuentes-Pesquera A, Connolly PJ, Pandey N, Moreno-Mazza S, Butler J, Borowski V, Middleton SA, Gruninger RH, Story JR, Napier C, Hollister B, Greenberger LM.

Mol Pharmacol. 2008 Feb;73(2):338-48. Epub 2007 Nov 1.

PMID:
17975007
23.

Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors.

Lin R, Chiu G, Yu Y, Connolly PJ, Li S, Lu Y, Adams M, Fuentes-Pesquera AR, Emanuel SL, Greenberger LM.

Bioorg Med Chem Lett. 2007 Aug 15;17(16):4557-61. Epub 2007 Jun 6.

PMID:
17574416
24.

The transition to an elongation complex by T7 RNA polymerase is a multistep process.

Bandwar RP, Ma N, Emanuel SA, Anikin M, Vassylyev DG, Patel SS, McAllister WT.

J Biol Chem. 2007 Aug 3;282(31):22879-86. Epub 2007 Jun 4.

25.

Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.

Lin R, Connolly PJ, Lu Y, Chiu G, Li S, Yu Y, Huang S, Li X, Emanuel SL, Middleton SA, Gruninger RH, Adams M, Fuentes-Pesquera AR, Greenberger LM.

Bioorg Med Chem Lett. 2007 Aug 1;17(15):4297-302. Epub 2007 May 16.

PMID:
17532631
26.

4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation.

Hughes TV, Emanuel SL, Beck AK, Wetter SK, Connolly PJ, Karnachi P, Reuman M, Seraj J, Fuentes-Pesquera AR, Gruninger RH, Middleton SA, Lin R, Davis JM, Moffat DF.

Bioorg Med Chem Lett. 2007 Jun 15;17(12):3266-70. Epub 2007 Apr 10.

PMID:
17481894
27.

Synthesis and biological study of 2-amino-4-aryl-5-chloropyrimidine analogues as inhibitors of VEGFR-2 and cyclin dependent kinase 1 (CDK1).

Huang S, Li R, Connolly PJ, Emanuel S, Fuentes-Pesquera A, Adams M, Gruninger RH, Seraj J, Middleton SA, Davis JM, Moffat DF.

Bioorg Med Chem Lett. 2007 Apr 15;17(8):2179-83. Epub 2007 Feb 2.

PMID:
17317182
28.

Synthesis of 3-(1H-benzimidazol-2-yl)-5-isoquinolin-4-ylpyrazolo[1,2-b]pyridine, a potent cyclin dependent kinase 1 (CDK1) inhibitor.

Huang S, Lin R, Yu Y, Lu Y, Connolly PJ, Chiu G, Li S, Emanuel SL, Middleton SA.

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1243-5. Epub 2006 Dec 15.

PMID:
17234412
29.

Histochemical alterations in one lung ventilation.

Yin K, Gribbin E, Emanuel S, Orndorff R, Walker J, Weese J, Fallahnejad M.

J Surg Res. 2007 Jan;137(1):16-20. Epub 2006 Nov 16.

PMID:
17112543
30.

Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor.

Seamon JA, Rugg CA, Emanuel S, Calcagno AM, Ambudkar SV, Middleton SA, Butler J, Borowski V, Greenberger LM.

Mol Cancer Ther. 2006 Oct;5(10):2459-67.

31.

Synthesis and biological study of 4-aminopyrimidine-5-carboxaldehyde oximes as antiproliferative VEGFR-2 inhibitors.

Huang S, Li R, Connolly PJ, Xu G, Gaul MD, Emanuel SL, Lamontagne KR, Greenberger LM.

Bioorg Med Chem Lett. 2006 Dec 1;16(23):6063-6. Epub 2006 Sep 18.

PMID:
16979339
32.

Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors.

Huang S, Li R, Connolly PJ, Emanuel S, Middleton SA.

Bioorg Med Chem Lett. 2006 Sep 15;16(18):4818-21. Epub 2006 Jul 25.

PMID:
16870444
33.

Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621.

Huang S, Connolly PJ, Lin R, Emanuel S, Middleton SA.

Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41. Epub 2006 May 6.

PMID:
16682186
34.

(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.

Ho CY, Ludovici DW, Maharoof US, Mei J, Sechler JL, Tuman RW, Strobel ED, Andraka L, Yen HK, Leo G, Li J, Almond H, Lu H, DeVine A, Tominovich RM, Baker J, Emanuel S, Gruninger RH, Middleton SA, Johnson DL, Galemmo RA Jr.

J Med Chem. 2005 Dec 29;48(26):8163-73.

PMID:
16366598
35.

The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.

Emanuel S, Rugg CA, Gruninger RH, Lin R, Fuentes-Pesquera A, Connolly PJ, Wetter SK, Hollister B, Kruger WW, Napier C, Jolliffe L, Middleton SA.

Cancer Res. 2005 Oct 1;65(19):9038-46.

36.

Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.

Kuo GH, Prouty C, Wang A, Emanuel S, Deangelis A, Zhang Y, Song F, Beall L, Connolly PJ, Karnachi P, Chen X, Gruninger RH, Sechler J, Fuentes-Pesquera A, Middleton SA, Jolliffe L, Murray WV.

J Med Chem. 2005 Jul 28;48(15):4892-909.

PMID:
16033269
37.

Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors.

Kuo GH, Deangelis A, Emanuel S, Wang A, Zhang Y, Connolly PJ, Chen X, Gruninger RH, Rugg C, Fuentes-Pesquera A, Middleton SA, Jolliffe L, Murray WV.

J Med Chem. 2005 Jul 14;48(14):4535-46.

PMID:
15999992
38.

1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.

Lin R, Connolly PJ, Huang S, Wetter SK, Lu Y, Murray WV, Emanuel SL, Gruninger RH, Fuentes-Pesquera AR, Rugg CA, Middleton SA, Jolliffe LK.

J Med Chem. 2005 Jun 30;48(13):4208-11.

PMID:
15974571
39.

3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation.

Lin R, Lu Y, Wetter SK, Connolly PJ, Turchi IJ, Murray WV, Emanuel SL, Gruninger RH, Fuentes-Pesquera AR, Adams M, Pandey N, Moreno-Mazza S, Middleton SA, Jolliffe LK.

Bioorg Med Chem Lett. 2005 May 2;15(9):2221-4.

PMID:
15837297
40.

Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.

Kuo GH, Wang A, Emanuel S, Deangelis A, Zhang R, Connolly PJ, Murray WV, Gruninger RH, Sechler J, Fuentes-Pesquera A, Johnson D, Middleton SA, Jolliffe L, Chen X.

J Med Chem. 2005 Mar 24;48(6):1886-900.

PMID:
15771433
41.

Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.

Zhang HC, Derian CK, McComsey DF, White KB, Ye H, Hecker LR, Li J, Addo MF, Croll D, Eckardt AJ, Smith CE, Li Q, Cheung WM, Conway BR, Emanuel S, Demarest KT, Andrade-Gordon P, Damiano BP, Maryanoff BE.

J Med Chem. 2005 Mar 24;48(6):1725-8.

PMID:
15771419
42.

A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.

Emanuel S, Gruninger RH, Fuentes-Pesquera A, Connolly PJ, Seamon JA, Hazel S, Tominovich R, Hollister B, Napier C, D'Andrea MR, Reuman M, Bignan G, Tuman R, Johnson D, Moffatt D, Batchelor M, Foley A, O'Connell J, Allen R, Perry M, Jolliffe L, Middleton SA.

Mol Pharmacol. 2004 Sep;66(3):635-47.

PMID:
15322256
43.

Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.

Kuo GH, Prouty C, DeAngelis A, Shen L, O'Neill DJ, Shah C, Connolly PJ, Murray WV, Conway BR, Cheung P, Westover L, Xu JZ, Look RA, Demarest KT, Emanuel S, Middleton SA, Jolliffe L, Beavers MP, Chen X.

J Med Chem. 2003 Sep 11;46(19):4021-31.

PMID:
12954055
44.

Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.

Zhang HC, White KB, Ye H, McComsey DF, Derian CK, Addo MF, Andrade-Gordon P, Eckardt AJ, Conway BR, Westover L, Xu JZ, Look R, Demarest KT, Emanuel S, Maryanoff BE.

Bioorg Med Chem Lett. 2003 Sep 15;13(18):3049-53.

PMID:
12941331
45.

High incidence of depression in the primary care setting.

Emanuel SF, Holland JC, Bedno SA, Earles JE.

Mil Med. 2002 Oct;167(10):iii-iv. No abstract available.

PMID:
12392241
46.

Protection against glutamate toxicity through inhibition of the p44/42 mitogen-activated protein kinase pathway in neuronally differentiated P19 cells.

Grant ER, Errico MA, Emanuel SL, Benjamin D, McMillian MK, Wadsworth SA, Zivin RA, Zhong Z.

Biochem Pharmacol. 2001 Aug 1;62(3):283-96.

PMID:
11434901
47.

Antimitotic drugs cause increased tumorigenicity of multidrug resistant cells.

Emanuel SL, Chamberlin HA, Cohen D.

Int J Oncol. 1999 Mar;14(3):487-94.

PMID:
10024681
48.

New vectors for manipulation and selection of functional yeast artificial chromosomes (YACs) containing human DNA inserts.

Emanuel SL, Cook JR, O'Rear J, Rothstein R, Pestka S.

Gene. 1995 Apr 3;155(2):167-74.

PMID:
7721086
49.

Identification and sequence of an accessory factor required for activation of the human interferon gamma receptor.

Soh J, Donnelly RJ, Kotenko S, Mariano TM, Cook JR, Wang N, Emanuel S, Schwartz B, Miki T, Pestka S.

Cell. 1994 Mar 11;76(5):793-802.

PMID:
8124716
50.

Sublocalization of the human interferon-gamma receptor accessory factor gene and characterization of accessory factor activity by yeast artificial chromosomal fragmentation.

Cook JR, Emanuel SL, Donnelly RJ, Soh J, Mariano TM, Schwartz B, Rhee S, Pestka S.

J Biol Chem. 1994 Mar 4;269(9):7013-8.

Supplemental Content

Loading ...
Support Center